Sequenom's Management Presents At Bank Of America Merrill Lynch 2012 Healthcare Conference (Transcript)

Sequenom Inc. (SQNM)

Bank of America Merrill Lynch 2012 Healthcare Conference Call

May 15, 2012 4:00 p.m. ET

Executives

Ron Lindsay, Ph.D. - Director and Executive Vice President, Research & Development

William Welsh - Senior Vice President, Diagnostics

Dirk van de Boom, Ph.D. - Senior Vice President, Research & Development

Analysts

Derik de Bruin - Bank of America Merrill Lynch

Presentation

Compare to:
Previous Statements by SQNM
» Sequenom's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Sequenom's Management Presents at Barclays Capital 2012 Global Healthcare Conference (Transcript)
» Sequenom's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Sequenom CEO Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)

Welcome to the afternoon session of the 2012 Bank of America Merrill Lynch Healthcare Conference. I’m Derik de Bruin, the life sciences, tools and diagnostics analyst and our first company up this afternoon is going to be Sequenom. Here today from Sequenom we have Ron Lindsay, Director and Executive VP of R&D. We also have William Welsh, Senior Vice President, Diagnostics, and Dirk van de Boom, Senior VP of R&D, with us here today and there’ll be a brief presentation and then we’ll open it up for questions and answers after that.

With that, thank you and look forward to hearing it.

Ron Lindsay

Thanks. Okay. All right. Thank you, Derrick, and good afternoon, everyone, and welcome to the Sequenom presentation and I’d like thank B of A for the opportunity to be here for the first time and, in keeping with the recommendation, we’ll probably show fewer slides than usual, but, hopefully, we can update you on some key points.

For the last two or three years the senior leadership team and Sequenom has been sometimes accused, rightly or wrongly, of being very conservative. This is the bags that we don’t to give up in the near future, but I think its fair to say six months into launch of a very important product, we’re actually pretty mildly excited, I’d have to say. I think we share with you some of the updates on that and we’ll have time for some Q&A at the end.

1 2 3 Next › Last »